Phuturdex › Diseases › Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drugs in development · updated 30 October 2026
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: drugs in development
As of 30 October 2026 there are 74 active clinical trials (recruiting or ongoing, phases I–III) on 68 drugs for leukemia, Myelogenous, Chronic, BCR-ABL Positive. 21 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TGRX-678 | III | 4 | NCT07489755 |
| ELVN-001 | III | 3 | NCT07905183 |
| Flumatinib | III | 2 | NCT07885293 |
| HS-10382 | III | 2 | NCT07885293 |
| OlverembatinibHQP1351 | III | 2 | NCT06423911 |
| Radotinib | III | 1 | NCT03459534 |
| CD19 | II | 1 | NCT03849651 |
| Dilanubicel | II | 1 | NCT03399773 |
| EBX-102 | II | 1 | NCT06355583 |
| MGTA 456 | II | 1 | NCT03674411 |
| MK-4208 | I–II | 1 | NCT06163430 |
| Vitamin D3 | II | 1 | NCT06508099 |
| AgenT-797 | I | 1 | NCT07758218 |
| CBX-250 | I | 1 | NCT06994676 |
| CD20 | I | 1 | NCT07166419 |
| CD34 | I | 1 | NCT05088356 |
| MGD024 | I | 1 | NCT05362773 |
| RimiducidAP1903 | I | 1 | NCT01494103 |
| TQB3911 | I | 1 | NCT06672263 |
| Vididencel | I | 1 | NCT07651878 |
| ZE74-0282-0001 | I | 1 | NCT07527221 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AsciminibABL001, Scemblix® | III | 10 | NCT04971226 |
| DasatinibPhyrago®, Sprycel® | III | 10 | NCT07885293 |
| ImatinibSTI571, Imkeldi® | III | 8 | NCT07885293 |
| NilotinibDanziten®, Cavhanza® | III | 8 | NCT07885293 |
| BosutinibBosulif® | III | 4 | NCT06423911 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 18 | NCT03622788 |
| FludarabineFludara, FLUDARABIN | I–II | 17 | NCT03622788 |
| Mycophenolate MofetilMycophenolate, Cellcept | I–II | 11 | NCT03192397 |
| TacrolimusEnvarsus XR, Prograf® | II | 9 | NCT06001385 |
| MelphalanEvomela®, Hepzato® | I–II | 8 | NCT03192397 |
| ThiotepaTepylute®, Tepadina And Sodium Chloride® | II | 6 | NCT06013423 |
| SirolimusRapamycin, Scomara® | I–II | 5 | NCT03192397 |
| BlinatumomabBlincyto® | II | 4 | NCT03849651 |
| BusulfanBusulphan, Busulfex® | II | 4 | NCT06001385 |
| MesnaUromitexan, Mesnex® | II | 4 | NCT03849651 |
Sorted by most advanced phase and number of active trials. Showing 15 of 47 drugs.
All 68 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Chronic phase chronic myelogenous leukemia 35 drugs
- Accelerated phase chronic myelogenous leukemia 28 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Acute myeloid leukemia 314 drugs
- Blast Crisis 32 drugs
- Myelodysplastic Syndromes 203 drugs
- Non-Hodgkin lymphoma 269 drugs
- Hodgkin lymphoma 93 drugs
- Myeloproliferative disorders 91 drugs
- Myelofibrosis 91 drugs
- Chronic lymphocytic leukemia 137 drugs
- Chronic myelomonocytic leukemia 90 drugs
Broader categories
- Neoplasm 671 drugs
- Bone marrow disease 14 drugs
- Hematologic Diseases 57 drugs
- Leukemia 153 drugs
- Myeloid leukemia 26 drugs
- Myeloproliferative disorders 91 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D015464 “Leukemia, Myelogenous, Chronic, BCR-ABL Positive”.